Nogitecan
Ovarian Seromucinous Carcinoma
Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04739800CT.gov Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | — | Active Not Recruiting | — | — | — |
NCT02502266CT.gov Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT02364713CT.gov MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Seromucinous Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nogitecan (this asset) | National Cancer Institute (NCI) | P2/3 | BB · 66 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Cediranib | National Cancer Institute (NCI) | P3 | BB |
| Olaparib | National Cancer Institute (NCI) | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | BB |
| Docetaxel | National Cancer Institute (NCI) | P3 | BB |
| Nivestim | University of Washington | P2 | B |
| Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine | Mayo Clinic | P2 | B |
+28 more in the Ovarian Seromucinous Carcinoma cohort
Other indications for Nogitecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P3 | BBB · 74 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
| Non-Small Cell Lung Carcinoma | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Nogitecan in Ovarian Seromucinous Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/nogitecan-ovarian-seromucinous-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →